1. 1
   Sekine, Y., K. Kikkawa, S. Honda, Y. Sasaki, S. Kawahara, A. Mizushima, S. Togi, M. Fujimuro, K. Oritani, T. Matsuda. STAP-2 facilitates insulin signaling through binding to CAP/c-Cbl and regulates adipocyte differentiation. Sci Rep.14, 5799 (2024) Sci Rep.
2. 2
   Kagohashi K, Sasaki Y, Ozawa K, Tsuchiya T, Kawahara S, Saitoh K, Ichii M, Toda J, Harada Y, Kubo M, Kitai Y, Muromoto R, Oritani K, Kashiwakura JI, Matsuda T. Role of Signal-Transducing Adaptor Protein-1 for T Cell Activation and Pathogenesis of Autoimmune Demyelination and Airway Inflammation. J Immunol212(6):951-961, 2024 J Immunol

Page Top

1. 1
   Sasaki Y, Kawahara S, Sekine Y, Kashiwakura JI, Oritani K, Matsuda T. Potential therapeutic applications of targeting signal-transducing adaptor protein-2 in autoimmune diseases Explor Immunol3:604–612, 2023 Explor Immunol
2. 2
   Kashiwakura JI, Kawahara S, Inagaki I, Inui K, Saitoh K, Kagohashi K, Sasaki Y, Kobayashi F, Kitai Y, Muromoto R, Oritani K, Matsuda T. STAP-2 negatively regulates BCR-mediated B cell activation by recruiting tyrosine-protein kinase CSK to LYN FEBS Lett.597:2433–2445, 2023 FEBS Lett.
3. 3
   Sasaki Y, Saitoh K, Kagohashi K, Toyoyuki O, Shoya K, Kitai Y, Muromoto R, Sekine Y, Ichii M, Yoshimura A, Oritani K, Kashiwakura JI, Matsuda T. STAP-2-derived peptide suppresses T cell receptor-mediated signals to initiate immune responses J Immunol211(5):755–766, 2023 J Immunol
4. 4
   Matsuda T. The Physiological and Pathophysiological Role of IL-6/STAT3-Mediated Signal Transduction and STAT3 Binding Partners in Therapeutic Applications. Biol. Pharm. Bull.2023;46, 364–378 Biol. Pharm. Bull.

Page Top

1. 1
   Kashiwakura JI, Oritani K, Matsuda T. The Functional Properties and Physiological Roles of Signal-Transducing Adaptor Protein-2 in the Pathogenesis of Inflammatory and Immune Disorders. Biomedicines2022, 10(12), 3079 Biomedicines
2. 2
   Muromoto R, Oritani K, Matsuda T. Role of tyrosine kinase 2 signals during progression of psoriasis. Explor Immunol2022;2:760-770 Explor Immunol
3. 3
   Matsuda T, Sasaki Y, Kagohashi K, Saitoh K, Sekine Y, Kashiwakura JI, Oritani K. Signal-transducing adaptor protein-2 modulates T-cell functions. Explor Immunol2022;2:771–782 Explor Immunol
4. 4
   Kameda T, Shide K, Kamiunten A, Kogure Y, Morishita D, Koya J, Tahira Y, Akizuki K, Yokomizo-Nakano T, Kubota S, Marutsuka K, Sekine M, Hidaka T, Kubuki Y, Kitai Y, Matsuda T, Yoda A, Ohshima T, Sugiyama M, Sashida G, Kataoka K, Ogawa S, Shimoda K. CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma. Commun Biol 5(1):1309, 2022 . Commun Biol
5. 5
   Hashimoto S, Hashimoto A, Muromoto R, Kitai Y, Oritani K, Matsuda T. Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance. Cells 11(16):2618, 2022 Cells
6. 6
   Muromoto R, Oritani K, Matsuda T IL-17 signaling is regulated through intrinsic stability control of mRNA during inflammation. AIMS Allergy and Immunology 6(3):188-199, 2022 AIMS Allergy and Immunology
7. 7
   Yamada S, Kitai Y, Tadokoro T, Takahashi R, Shoji H, Maemoto T, Ishiura M, Muromoto R, Kashiwakura JI, Ishii KJ, Maenaka K, Kawai T, Matsuda T Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation J Immunol 209(1):171-179, 2022 J Immunol
8. 8
   Saitoh K, Kashiwakura JI, Kagohashi K, Sasaki Y, Kawahara S, Sekine Y, Kitai Y, Muromoto R, Ichii M, Nakatsukasa H, Yoshimura A, Oritani K, Matsuda T STAP-2 Is a Novel Positive Regulator of TCR-Proximal Signals J Immunol 209(1):57-68, 2022 J Immunol
9. 9
   Muromoto R, Sato A, Komori Y, Nariya K, Kitai Y, Kashiwakura JI, Matsuda T Regulation of NFKBIZ gene promoter activity by STAT3, C/EBPβ, and STAT1. Biochem Biophys Res Commun 613:61-66, 2022 Biochem Biophys Res Commun
10. 10
    Sekine Y, Kikkawa K, Witthuhn B, Kashiwakura J, Muromoto R, Kitai Y, Fujimuro M, Oritani K, Matsuda T A novel intramolecular negative regulation of mouse Jak3 activity by tyrosine 820. Int. Immunol. 34(6): 303-312, 2022 Int. Immunol.
11. 11
    Ichii M, Oritani K, Toda J, Hosen N, Matsuda T, Kanakura Y Signal-transducing adaptor protein-1 and -2 in hematopoiesis and diseases. Exp. Hematol. 105: 10-17, 2022 Exp. Hematol.
12. 12
    Muromoto R, Oritani K, Matsuda T Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J. Biol. Chem. 13: 1-14, 2022 World J. Biol. Chem.

Page Top

1. 1
   Sasaki Y*, Saitoh K*, Kagohashi K, Kitai Y, Muromoto R, Oritani K, Kashiwakura J, Matsuda T Pivotal role of signal-transducing adaptor protein-2 in pathogenesis of autoimmune hepatitis. Biol. Pharm. Bull. 44: 1898-1901, 2021 (*equivalent co-authors in the article) Biol. Pharm. Bull.
2. 2
   Matsuda T and Oritani K Possible therapeutic applications of targeting STAP proteins in cancer. Biol. Pharm. Bull. 44: 1810-1818, 2021 Biol. Pharm. Bull.
3. 3
   Ishimura K, Fukuda H, Fujiwara K, Muromoto R, Hirashima K, Murakami Y, Watanabe M, Ishihara J, Matsuda T, Shuto S Synthesis of Resolvin E1 and its conformationally restricted cyclopropane congeners with potent anti-inflammatory effect. ACS Med. Chem. Lett. 21: 256-261, 2021 ACS Med. Chem. Lett.
4. 4
   Muromoto R, Shimoda K, Oritani K, Matsuda T Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases. Biol. Pharm. Bull. 44: 895-901, 2021 Biol. Pharm. Bull.
5. 5
   Matsuda T and Oritani K STAP-2 adaptor protein regulates multiple steps of immune and inflammatory responses. Biol. Pharm. Bull. 44: 895-901, 2021 Biol. Pharm. Bull.
6. 6
   Kashiwakura J, Koizumi N, Saitoh K, Kagohashi K, Sasaki Y, Kobayashi F, Kawahara S, Yamauchi Y, Kitai Y Muromoto R, Oritani K, Matsuda T Signal-transducing adaptor protein-2 has a nonredundant role for IL-33-triggered mast cell activation. Biochem. Biophys. Res. Commun. 572: 80-85, 2021 Biochem. Biophys. Res. Commun.
7. 7
   Aioi A, Muromoto R, Mogami S, Nishikawa M, Ogawa S, Matsuda T Porcine placenta xtract reduced wrinkle formation by potentiating epidermal hydration. Scientific Research 11: 101-109, 2021 Scientific Research
8. 8
   Ishiura M, Kitai Y, Kashiwakura J, Muromoto R, Toda J, Ichii M, Oritani K, Matsuda T Positive interactions between STAP-1 and BCR-ABL influence chronic myeloid leukemia cell proliferation and survival. Biochem. Biophys. Res. Commun. 556: 185-191, 2021 Biochem. Biophys. Res. Commun.
9. 9
   Togi S, Togi M, Nagashima S, Kitai Y, Muromoto R, Kashiwakura J, Miura T, Matsuda T Implication of NF-κB Activation on Ozone-Induced HO-1 Activation. BPB Reports 4: 59-63, 2021 BPB Reports
10. 10
    Mishima S*, Kashiwakura J*, Toyoshima S*, Sasaki-Sakamoto T, Sano Y, Nakanishi K, Matsumoto K, Okayama Y Higher PGD2 production by synovial mast cells from rheumatoid asthritis patients compared with osteoarthritis patients via miR-199a-3p/prostaglandin synthetase 2 axis. Sci Rep. 11: 5738, 2021 (*equivalent co-authors in the article) Sci Rep.
11. 11
    Kitai Y, Ishiura M, Saitoh K, Matsumoto N, Owashi K, Yamada S, Muromoto R, Kashiwakura JI, Oritani K, Matsuda T CD47 promotes T-cell lymphoma metastasis by upregulating AKAP13-mediated RhoA activation. Int. Immunol. 33: 273-280, 2021 Int. Immunol.
12. 12
    Kashiwakura J*, Yoshihara M*, Saitoh K, Kagohashi K, Sasaki Y, Kobayashi F, Inagaki I, Kitai Y, Muromoto R, Matsuda T Propolis suppresses cytokine production in activated basophils and basophil-mediated skin and intestinal allergic inflammation in mice. Allergol. Int. 70: 360-367, 2020 (*equivalent co-authors in the article) Allergol. Int.
13. 13
    Saito H, Ichii M, Toda J, Kitai Y, Muromoto R, Kashiwakura JI, Saitoh K, Tanimura A, Yokota T, Shibayama H, Matsuda T, Oritani K, Kanakura Y, Hosen N Graft-versus-host disease develops in mice transplanted with lymphocyte-depleted bone marrow cells from signal-transducing adaptor protein-2 transgenic mice. Biochem. Biophys. Res. Commun. 537: 118-124, 2021 Biochem. Biophys. Res. Commun.
14. 14
    Ichii M, Oritani K, Toda J, Saito H, Shi H, Shibayama H, Motooka D, Kitai Y, Muromoto R, Kashiwakura JI, Saitoh K, Okuzaki D, Matsuda T, Kanakura Y Signal-transducing adaptor protein-2 delays recovery of B lineage lymphocytes during hematopoietic stress. Haematologica 106: 424-436, 2021 Haematologica

Page Top

1. 1
   Kashiwakura J*, Saitoh K*, Ihara T, Sasaki Y, Kagohashi K, Enohara S, Morioka Y, Watarai H, Muromoto R, Kitai Y, Iwabuchi K, Oritani K, Matsuda T Expression of signal-transducing adaptor protein-1 attenuates experimental autoimmune hepatitis via down-regulating activation and homeostasis of invariant natural killer T cells. PLOS ONE 15:e0241440, 2020 (*equivalent co-authors in the article) PLOS ONE
2. 2
   Fukuda H, Ikeda H, Muromoto R, Hirashima K, Ishimura K, Fujiwara K, Aoki-Saito H, Hisada T, Watanabe M, Ishihara J, Matsuda T, Shuto S Synthesis of Resolvin E3, a Proresolving Lipid Mediator, and Its Deoxy Derivatives: Identification of 18-Deoxy-resolvin E3 as a Potent Anti-Inflammatory Agent. J. Org.. Chem. 85:514190-14200, 2020 J. Org.. Chem.
3. 3
   Toda J, Ichii M, Oritani K, Shibayama H, Tanimura A, Saito H, Yokota T, Motooka D, Okuzaki D, Kitai Y, Muromoto R, Kashiwakura J, Matsuda T, Hosen N, Kanakura Y Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML. Oncogene 39:5601-5615, 2020 Oncogene
4. 4
   Murakami Y, Fukuda H, Muromoto R, Hirashima K, Ishimura K, Fujiwara K, Ishihara J, Matsuda T, Watanabe M, Shuto S Design and Synthesis of Benzene Congeners of Resolvin E2, a Proresolving Lipid Mediator, as Its Stable Equivalents. ACS Med. Chem. Lett. 18:6224-6227, 2020 ACS Med. Chem. Lett.
5. 5
   Hirashima K, Muromoto R, Minoguchi H, Matsumoto T, Kitai Y, Kashiwakura J, Shimoda K, Oritani K, Matsuda T The mechanism of Tyk2 deficiency-induced immunosuppression in mice involves robust IL-10 production in macrophages. Cytokine 130:155077, 2020 Cytokine

Page Top

1. 1
   Nishida K, Hasegawa A, Yamasaki S, Uchida R, Ohashi W, Kurashima Y, Kunisawa J, Kimura S, Iwanaga T, Watarai H, Hase K, Ogura H, Nakayama M, Kashiwakura J, Okayama Y, Kubo M, Ohara O, Kiyono H, Koseki H, Murakami M, Hirano T Mast cells play role in wound healing through the ZnT2/GPR39/IL-6 axis. Sci. Rep. 9:10842, 2019 Sci. Rep.
2. 2
   Muromoto R, Tawa K, Ohgakiuchi Y, Sato A, Saino Y, Hirashima K, Minoguchi H, Kitai Y, Kashiwakura J, Shimoda K, Oritani K, Matsuda T IκB-ζ Expression Requires Both TYK2/STAT3 Activity and IL-17–Regulated mRNA Stabilization. ImmunoHorizons 3: 172-185, 2019 ImmunoHorizons
3. 3
   Kashiwakura J, Ando T, Karasuyama H, Kubo M, Matsumoto K, Matsuda T, Kawakami T. The basophil-IL-4-mast cell axis is required for food allergy. Allergy 74:1992-1996, 2019 Allergy
4. 4
   Izaki S, Toyoshima S, Endo T, Kanegae K, Nunomura S, Kashiwakura J, Sasaki-Sakamoto T, Nakamura R, Akiyama H, Ra C, Hayama K, Terui T, Okayama Y Differentiation between control subjects and patients with chronic spontaneous urticaria based on the ability of anti-IgE autoantibodies (AAbs) to induce FcεRI crosslinking, as compared to anti-FcεRIα AAbs. Allergol. Int. 68:342-351, 2019 Allergol. Int.
5. 5
   Kashiwakura J*, Yamashita S*, Yoshihara M*, Inui K, Saitoh K, Sekine Y, Muromoto R, Kitai Y, Oritani K, Matsuda T STAP-2 positively regulates FcεRI-mediated basophil activation and basophil-dependent allergic inflammatory reaction. Int. Immunol. 31:349-356, 2019 (*equivalent co-authors in the article) Int. Immunol.
6. 6
   Ohgakiuchi Y, Saino Y, Muromoto R, Komori Y, Sato A, Hirashima K, Kitai Y, Kashiwakura J, Oritani K, Matsuda T Dimethyl fumarate dampens IL-17-ACT1-TBK1 axis-mediated phosphorylation of Regnase-1 and suppresses IL-17-induced IκB-ζ expression. Biochem. Biophys. Res. Commun. 521:957-963, 2019 Biochem. Biophys. Res. Commun.

Page Top

1. 1
   Matsuno T, Toyoshima S, Sakamoto-Sasaki T, Kashiwakura J, Matsuda A, Watanabe Y, Azuma H, Kawana K, Yamamoto T, Okayama Y Characterization of human decidual mast cells and establishment of a culture system. Allergol. Int. 67:S18-S24 , 2018 Allergol. Int.
2. 2
   Kanada R, Tanabe M, Muromoto R, Sato Y, Kuwahara T, Fukuda H, Arisawa M, Matsuda T, Watanabe M, Shuto S Synthesis of Chiral cis-Cyclopropane Bearing Indole and Chromone as Potential TNFα Inhibitors. J. Org. Chem. 83:7672-7682 , 2018 J. Org. Chem.

Page Top

1. 1
   Doré KA, Kashiwakura J, McDonnell JM, Gould HJ, Kawakami T, Sutton BJ, Davies AM Crystal structures of murine and human Histamine-Releasing Factor (HRF/TCTP) and a model for HRF dimerisation in mast cell activation. Mol. Immunol. 93:216-222 , 2017 Mol. Immunol.
2. 2
   Kitai Y, Iwakami M, Saitoh K, Togi S, Isayama S, Sekine Y, Muromoto R, Kashiwakura J, Yoshimura A, Oritani K, Matsuda T STAP-2 promotes prostate cancer growth by enhancing EGFR stabilization J. Biol. Chem. 292(47):19392-19399 , 2017 J. Biol. Chem.
3. 3
   Kashiwakura J and Kawakami T Expression of TCTP-Related Genes. J. Genet. Disor. Genet. Rep. 6:2 , 2017 J. Genet. Disor. Genet. Rep.
4. 4
   Ando T*, Kashiwakura J*, Itoh-Nagato N, Yamashita H, Baba M, Kawakami Y, Tsai SH, Inagaki N Takeda K, Iwata T, Shimojo N, Fujisawa T, Nagao M, Matsumoto K, Kawakami Y, Kawakami T Histamine-releasing factor as a food allergy amplifier. J. Clin. Invest. 127(12):4541–4553 , 2017 (*equivalent co-authors in the article)J. Clin. Invest.
5. 5
   Kitai, Y., T. Kawasaki, T. Sueyoshi, K. Kobiyama, K. J. Ishii, J. Zou, S. Akira, T. Matsuda, T. Kawai. DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity. J. Immunol. 198:1649-1659, 2017 J. Immunol.
6. 6
   Okamura Y, Mishima S, Kashiwakura J, Sasaki-Sakamoto T, Toyoshima S, Kuroda K, Saito S, Tokuhashi Y, Okayama Y The dual regulation of substance P-mediated inflammation via human synovial mast cells in rheumatoid arthritis. Allergol. Int. 66:S9-S20 , 2017 Allergol. Int.
7. 7
   Saitoh K, Tsuchiya T, Kashiwakura J, Muromoto R, Kitai Y, Sekine Y, Oritani K, Matsuda T STAP-2 interacts with Pyk2 and enhances Pyk2 activity in T-cells. Biochem. Biophys. Res. Commun. 488:81-87, 2017 Biochem. Biophys. Res. Commun.
8. 8
   Matsumoto N, Kon S, Nakatsuru T, Miyashita T, Inui K, Saitoh K, Kitai Y, Muromoto R, Kashiwakura J, Uede T, Matsuda T A Novel α9 Integrin Ligand, XCL1/lymphotactin, is Involved in the Development of Murine Models of Autoimmune Diseases. J. Immunol. 199:82-90, 2017 J. Immunol.
9. 9
   Takahashi M, Muromoto R, Kojima H, Takeuchi S, Kitai Y, Kashiwakura J, Matsuda T Biochanin A enhances RORγ activity through STAT3-mediated recruitment of NCOA1. Biochem. Biophys. Res. Commun. 489:503-508, 2017 Biochem. Biophys. Res. Commun.

Page Top

1. 1
   Fukuda, H., R. Muromoto, Y. Takakura, K. Ishimura, R. Kanada, D. Fushihara, M. Tanabe, K. Matsubara, T. Hirao, K. Hirashima, H. Abe, M. Arisawa, T. Matsuda, S. Shuto. Design and Synthesis of Cyclopropane Congeners of Resolvin E2, an Endogenous Proresolving Lipid Mediator, as Its Stable Equivalents. Org. Lett. 18:6224-6227, 2016
2. 2
   Togi, S., Y. Hatano, R. Muromoto, E. Kawanishi, O. Ikeda, K. Hirashima, S. Kon, Y. Kitai, T. Yasui, K. Oritani, T. Matsuda. Caspase-dependent cleavage regulates protein levels of Epstein-Barr virus-derived latent membrane protein 1. FEBS Lett. 590:808-818, 2016 PubMed
3. 3
   Takahashi, A., K., Kuroki, Y. Okabe, Y. Kasai, N. Matsumoto, C. Yamada, C, T. Takai, T. Ose, S. Kon, T. Matsuda, K. Maenaka. The immunosuppressive effect of domain-deleted dimer of HLA-G2 isoform in collagen-induced arthritis mice. Hum Immunol. 21. pii: S0198-8859 (16) 00011-2, 2016
4. 4
   Togi, S., R. Muromoto, K. Hirashima, Y. Kitai, T. Okayama, O. Ikeda, N. Matsumoto, S. Kon, Y. Sekine, K. Oritani, T. Matsuda. A new STAT3-binding partner, ARL3, enhances the phosphorylation and nuclear accumulation of STAT3. J. Biol. Chem. 291: 11161-11171, 2016 PubMed
5. 5
   Matsui, Y, S. Kon, T. Funakoshi, T. Miyashita, T. Matsuda, N. Iwasaki. Increased expression of αv integrin as a regulator of fibrosis in Dupuytren's nodules. J Hand Surg Eur Vol. 2016 Mar 11. pii: 1753193416635489.
6. 6
   Muromoto, R., T. Hirao, K. Tawa, K. Hirashima, S. Kon, Y. Kitai, T. Matsuda. IL-17A plays a central role in the expression of psoriasis signature genes through induction of IκB-ζ in keratinocytes. Int. Immunol. 28:443-452, 2016 PubMed
   EDITOR'S CHOICE: FEATURED ARTICLES
7. 7
   Saitoh, K., S. Kon, T. Nakatsuru, K. Inui, T. Ihara, N. Matsumoto, Y. Kitai, R. Muromoto, T. Matsuda. Anti-IL-17A blocking antibody reduces cyclosporin A-induced relapse in experimental autoimmune encephalomyelitis mice. Biochem Biophys Rep. 8:139-145, 2016 ScienceDirect

Page Top

1. 1Kato, M., R. Muromoto, S. Togi, M. Iwakami, Y. Kitai, S. Kon, K. Oritani and T.Matsuda PML suppresses IL-6-induced STAT3 activation by interfering with STAT3 and HDAC3 interaction Biochem. Biophys. Res. Commun. 461: 366-371, 2015
2. 2Togi, S., M. Nakasuji, R. Muromoto, O. Ikeda, K. Okabe, Y. Kitai, S. Kon, K. Oritani and T. Matsuda Kaposi's sarcoma-associated herpesvirus-encoded LANA associates with glucocorticoid receptor and enhances its transcriptional activities Biochem. Biophys. Res. Commun. 463: 395-400, 2015
3. 3Kubo, K., M. Iwakami, R. Muromoto, T. Inagaki, Y. Kitai, S. Kon, Y.Sekine, K. Oritani and T.Matsuda CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells Biochem. Biophys. Res. Commun. 463: 825-831, 2015
4. 4Sekine Y, S. Togi, R. Muromoto, S. Kon, Y. Kitai, A. Yoshimura, K. Oritani, T. Matsuda STAP-2 protein expression in B16F10 melanoma cells positively regulates protein levels of tyrosinase, which determines organs to infiltrate in the body J. Biol. Chem. 290: 17462-17473, 2015
5. 5Kojima H, Takeda Y, Muromoto R, Takahashi M, Hirao T, Takeuchi S, Jetten AM, Matsuda T. Isoflavones enhance interleukin-17 gene expression via retinoic acid receptor-related orphan receptors α and γ Toxicology. 329:32-39, 2015
6. 6Ichii, M., Oritani K, Fujita N, Saitoh N, Sekine Y, Muromoto R, Kon S, Saitoh K, Matsuda T, Kanakura Y.Regulation of B lymphopoiesis by signal-transducing adaptor protein-2, STAP-2.Haematologica 99:175, 2015
7. 7Matsuda,T., R. Muromoto, Y. Sekine, S. Togi, Y. Kitai, S. Kon, K. Oritani STAT3 regulation by novel binding partners World J Biol. Chem. 6:324-332, 2015

Page Top

1. 1Ishizaki, M., R. Muromoto, T. Akimoto, Y. Sekine, S. Kon, M. Diwan, H. Maeda, S. Togi, K. Shimoda, K. Oritani and T. Matsuda Tyk2 is a therapeutic target for psoriasis-like skin inflammation Int. Immunol.26:257-267, 2014
2. 2Fujita, N., K. Oritani, M. Ichii, T. Yokota, N. Saitoh, D. Okuzaki, Y. Sekine, S. Kon, R. Muromoro, K. Saitoh, A. Yoshimura, T. Matsuda, Y. Kanakura Signal-Transducing Adaptor Protein-2 regulates macrophage migration into inflammatory sites during dextran sodium sulfate-induced colitis Eur. J. Immunol.44:1791-1801, 2014
3. 3Sekine, Y., K. Nishida, S. Yamasaki, R. Muromoto, S. Kon, J. Kashiwakura, K. Saitoh, S. Togi, A. Yoshimura, K. Oritani and T. Matsuda Signal-transducing adaptor protein-2 controls the IgE-mediated, mast cell-mediated anaphylactic responses J. Immunol.192:3488-3495, 2014
4. 4Kouro, H., S. Kon, N. Matsumoto, T. Miyashita, A. Kakuchi, D. Ashitomi, K. Saitoh, T. Nakatsuru, S. Togi, R. Muromoto, and T. Matsuda The novel α4B murine α4 integrin splicing variant inhibits α4-dependent cell adhesion J. Biol. Chem.289:16389-16398, 2014
5. 5Vicente Sanchez-Mut, J. Aso, E., Holger, H., Matsuda, T., Bock, C., Ferrer, I. and M. Esteller Promoter Hypermethylation of the Phosphatase DUSP22 Mediates PKA- Dependent TAU Phosphorylation and CREB Activation in Alzheimer's Disease Hippocampus 24: 363-368, 2014
6. 6Kon, S. Nakayama, Y., Matsumoto, N., Ito, K., Kanayama, M., Kimura, C., Kouro, H., Ashitomi, D., Matsuda, T., Uede, T. A Novel Cryptic Binding Motif, LRSKSRSFQVSDEQY, in the C-Terminal Fragment of MMP-3/7-Cleaved Osteopontin as a Novel Ligand for alpha 9b1 Integrin Is Involved in the Anti-Type II Collagen Antibody-Induced Arthritis PLoS ONE 9(12): e116210, 2014

Page Top

1. 1Togi, S., K. Shiga, R. Muromoto, M. Kato, Y. Souma, Y. Sekine, S. Kon, K. Oritani and T. Matsuda Y14 positively regulates TNF-alpha-induced NF-kappaB transcriptional activity via interacting RIP1 and TRADD beyond an exon-junction complex protein. J. Immunol. 191:1436-1444, 2013
2. 2Muromoto, R., M. Nakajima, K. Hirashima, T. Hirao, S. Kon, K. Shimoda, K. Oritani, T. Matsuda Jun activation domain-binding protein 1 (JAB1) is required for the optimal response to interferons J. Biol. Chem. 288:30969-30979, 2013

Page Top

1. 1Kojima, H., R. Muromoto, M. Takahashi, S. Takeuchi, Y. Takeda, A. M. Jetten and T. Matsuda Inhibitory effects of azole-type fungicides on interleukin-17 gene expression via retinoic acid receptor-related orphan receptors α and γ.Toxicol Appl. Pharmacol. 259:338-345, 2012
2. 2Shide, K., T. Kameda, H. Shimoda, T. Yamaji, H. Abe, A. Kamiunten, M. Sekine, T. Hidaka, K. Katayose, Y. Kubuki, S. Yamamoto, T. Miike, H. Iwakiri, S. Hasuike, K. Nagata, K. Marutsuka, A. Iwama, T. Matsuda, A. Kitanaka and K. Shimoda TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 26:2216-2223, 2012
3. 3Sekine, Y., O. Ikeda, A. Mizushima, Y. Ueno, R. Muromoto, A. Yoshimura, Y. Kanakura, , K. Oritani and T. Matsuda STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis. Oncogene 26: 6038-6049, 2012
4. 4Sekine, Y., C. Yamamoto, M. Kakisaka, R. Muromoto, S. Kon, D. Ashitomi, N. Fujita, A. Yoshimura, K. Oritani, and T. Matsuda Signal-transducing adaptor protein-2 modulates Fas-mediated T-cell apoptosis by interacting with caspase-8. J. Immunol. 188:6194-6204, 2012
5. 5Matsuda, T., S. Kon, and Muromoto, R. Molecular targeted therapy for JAK/STAT signaling. Nihon Rinsho 8: 45-51, 2012
6. 6Muromoro, R Death domain-associatedprotein(DAXX)-mediated regulation of transcription and cell death. YAKUGAKU ZASSHI 132: 979-984, 2012

Page Top

1. 1Ikeda, O., A. Mizushima, Y. Sekine, C. Yamamoto, R. Muromoto, A. Nanbo, K. Oritani, A. Yoshimura and T. Matsuda Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells. Cancer Sci. 102: 756-761, 2011
2. 2Peng, D-J., M. Zeng, R. Muromoto, T. Matsuda, K. Shimoda, M. Subramaniam, T. C Spelsberg, W-Z. Wei1, and K. V. Poojary Non-canonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. J. Immunol. 186: 5638-5647, 2011
3. 3Togi, S., O. Ikeda, S. Kamitani, M. Nakasuji, Y. Sekine, R. Muromoto, A. Nanbo, K. Oritani, T. Kawai, S. Akira, and T. Matsuda Zipper-interacting protein kinase modulates canonical Wnt/beta-catenin signaling through interacting with Nemo-like kinase and T-cell factor 4. J. Biol. Chem. 286: 19170-19177, 2011
4. 4Ishizaki, M., T. Akimoto, R. Muromoto, M. Yokoyama, Y. Ohshiro, Y. Sekine, H. Maeda, K. Shimoda, K. Oritani and T. Matsuda　Involvement of Tyk2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J. Immunol. 187: 181-189, 2011
5. 5Ishizaki, M., R. Muromoto,T. Akimoto, Y. Ohshiro, M. Takahashi, Y. Sekine, H. Maeda, K. Shimoda, K. Oritani and T. Matsuda Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Int. Immunol. 23: 575-582, 2011
6. 6Kamitani, S., S. Togi, O. Ikeda, M. Nakasuji, A. Sakauchi, Y. Sekine, R. Muromoto, K. Oritani and T. Matsuda Kruppel-associated box-associated protein 1 negatively regulates TNF-alpha-induced NF-kappaB transcriptional activity by influencing the interactions among STAT3, p300, and NF-kappaB/p65. J. Immunol. 187: 2476-2483, 2011
7. 7Tanaka, T., Y. Yamamoto, R. Muromoto, O. Ikeda, Y. Sekine, M. J. Grusby, T. Kaisho and T. Matsuda PDLIM2 inhibits T helper 17 cell development and granulomatous inflammation through degradation of STAT3. Sci. Signal. 4, ra85, 2011

Page Top

1. 1Ikeda, O. ,Y. Miyasaka, R.Yoshida, A. Mizushima, K. Oritani, Y. Sekine, M. Kuroda, T. Yasui, M. Fujimuro, R. Muromoto, A. Nanbo, and T. Matsuda BS69 cooperates with TRAF3 in the regulation of Epstein-Barr virus-derived LMP1/CTAR1-induced NF-kappaB activation FEBS Lett. 584: 865-872, 2010
2. 2Sekine, Y A Novel Adaptor Protein, STAP-2 Functions as a Signal Modulator in Immune System YAKUGAKU ZASSHI 130: 769-775, 2010
3. 3Muromoto, R., M. Kuroda, S. Togi, Y. Sekine, A. Nanbo, K. Shimoda, K. Oritani and T. Matsuda Functional involvement of Daxx in gp130-mediated cell growth and survival in BaF3 cells. Eur. J. Immunol. 40: 3570-3580, 2010
4. 4Ikeda, O., Y. Sekine, A. Mizushima, M. Nakasuji, Y. Miyasaka, C. Yamamoto, R. Muromoto, A. Nanbo, K. Oritani, A. Yoshimura and T. Matsuda Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells. J. Biol. Chem. 285: 38093-38103, 2010

Page Top

1. 1Sekine, Y., O. Ikeda, S. Tsuji, C. Yamamoto, R. Muromoto, A. Nanbo, K. Oritani, A.Yoshimura and T. Matsuda Signal-Transducing Adaptor Protein-2 Regulates Stromal Cell-Derived Factor-1alpha-Induced Chemotaxis in T Cells J. Immunol. 183: 7966-7974, 2009
2. 2Yamamoto, M., D. M. Standley, S. Takashima, H. Saiga, M. Okuyama, H. Kayama, E. Kubo, H. Ito, M. Takaura, T. Matsuda, D. Soldati-Favre, and K. Takada A single polymorphic amino acid replacement in Toxoplasma gondii ROP16 influences its direct Stat3 activation J. Exp. Med. 206: 2747-2760, 2009
3. 3Sekine, Y., C. Yamamoto, O. Ikeda, R. Muromoto, A. Nanbo, K. Oritani, A. Yoshimura and T. Matsuda The protein content of an adaptor protein, STAP-2 is controlled by E3 ubiquitin ligase Cbl Biochem. Biophys. Res. Commun. 384: 187-192, 2009
4. 4Ikeda, O., Y. Miyasaka, Y. Sekine, A. Mizushima, R. Muromoto, A. Nanbo, A. Yoshimura and T. Matsuda STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation Biochem. Biophys. Res. Commun. 384: 71-75, 2009
5. 5Ikeda, O., Y. Sekine, A. Mizushima, K. Oritani, T. Yasui, M. Fujimuro, R. Muromoto, A. Nanbo, and T. Matsuda BS69 negatively regulates the canonical NF-κB activation induced by Epstein-Barr virus-derived LMP1 FEBS Lett. 583: 1567-1574, 2009
6. 6Ikeda, O., S. Togi, S. Kamitani,R. Muromoto, Y. Sekine, A. Nanbo, M. Fujimuro, and T. Matsuda Silencing Mediator of Retinoic acid and Thyroid hormone Receptor Regulates Enhanced Activation of Signal Transducer and Activator of Transcription 3 by Epstein-Barr Virus-derived Epstein-Barr Nuclear Antigen 2 Biol. Pharm. Bull.32: 1283-1285, 2009
7. 7Muromoto R., N. Taira, O. Ikeda, K. Shiga, S. Kamitani, S. Togi, S. Kawakami, Y. Sekine, A. Nanbo, K. Oritani, and T. Matsuda The exon-junction complex proteins, Y14 and MAGOH regulate STAT3 activation Biochem. Biophys. Res. Commun. 382: 63-68, 2009
8. 8Togi, S., S. Kamitani, S. Kawakami, O. Ikeda, R. Muromoto, A. Nanbo, and T. Matsuda HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A Biochem. Biophys. Res. Commun. 379: 616-620, 2009
9. 9Takeuchi, S., T. Takahashi, Y. Sawada, M. Iida, T. Matsuda and H. Kojima Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using chinese hamster ovary cells Biol. Pharm. Bull. 32:195-202, 2009
10. 10Muromoto, R., O. Ikeda, K. Okabe, S. Togi, S. Kamitani, M. Fujimuro, S. Harada, K. Oritani and T. Matsuda Epstein-Barr virus-derived EBNA2 regulates STAT3 activation Biochem. Biophys. Res. Commun. 378: 439-443, 2009

Page Top

1. 1Ikeda,O., Y. Sekine, R. Muromoto, N. Ohbayashi, A. Yoshimura and T. Matsuda Enhanced c-Fms/M-CSF receptor signaling and wound-healing process in bone marrow-derived macrophages of STAP-2 deficient mice Biol. Pharm. Bull. 31: 1790-1793, 2008
2. 2Ikeda,O., Y. Sekine, T. Yasui, K. Oritani, K. Sugiyma, R. Muromoto, N. Ohbayashi, A. Yoshimura and T. Matsuda STAP-2 negatively regulates both canonical and non-canonical NF-κB activation induced by Epstein-Barr virus-derived LMP1 Mol. Cell. Biol. 28: 5027-5042, 2008
3. 3Ohbayashi, N., K. Okada, S. Kawakami, S. Togi, N. Sato, O. Ikeda, S. Kamitani, R. Muromoto, Y. Sekine, T. Kawai, S. Akira, and T. Matsuda Physical and functional interactions between ZIP kinase and UbcH5 Biochem. Biophys. Res. Commun. 372: 708-712, 2008
4. 4Ohbayashi, N., N. Taira, S. Kawakami, S. Togi, N. Sato, O. Ikeda, S. Kamitani, R. Muromoto, Y. Sekine,and T. Matsuda An RNA biding protein, Y14 interacts with and modulates STAT3 activation Biochem. Biophys. Res. Commun. 372: 475-479, 2008
5. 5Ohbayashi, N., Kawakami, S., Muromoto, R., Togi, S., Ikeda, O., Kamitani, S., Sekine, Y., Honjoh, T., and T. Matsuda The IL-6 family of cytokines modulates STAT3 activation by desumoylation of PML through SENP1 induction Biochem. Biophys. Res. Commun. 371: 823-828, 2008
6. 6Tsuruma, R., Ohbayashi, N., Kamitani, S., Ikeda, O., Sato, N., Muromoto, R., Sekine, Y., Oritani, K., and T. Matsuda Physical and functional interactions between STAT3 and KAP1 Oncogene 27: 3054-3059, 2008
7. 7Kamitani, S., Ohbayashi, N., Ikeda, O., Togi, S., Muromoto, R., Sekine, Y., Ohta, K., Ishiyama, H., and T. Matsuda KAP1 regulates type I interferon/STAT1-mediated IRF-1 gene expression Biochem. Biophys. Res. Commun. 370: 366-370, 2008
8. 8Imoto, S., Ohbayashi, N., Ikeda, O., Kamitani, S., Muromoto, R., Sekine, Y., and T. Matsuda Sumoylation of Smad3 stimulates its nuclear export during PIASy-mediated suppression of TGF-beta signaling Biochem. Biophys. Res. Commun. 370: 359-365, 2008
9. 9Muromoto, R., Sekine, Y., Imoto, S., Ikeda, O., Okayama, T., Sato, N. and T. Matsuda BART is essential for nuclear retention of STAT3 Int. Immunol. 20: 395-403, 2008
10. 10Shide, K., Shimoda, K. S., Kumano, T., Karube, K., Kameda, T., Takenaka, K., Oku, S., Abe, H., Katayose, K. S., Kubiki, Y., Kusumo, K., Hasuike, S., Tahara, Y., Nagata, K., Matsuda, t., Ohshima, K., Harada, M., and Shimoda, K. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F Leukemia 22: 87-95, 2008
11. 11Takeuchi, S., M. Iida, H.Yabushita, T. Matsuda and H. Kojima In vitro screening for aryl hydrocarbon receptor agonistic activity in 200 pesticides using a highly sensitive reporter cell line, DR-EcoScreen cells, and in vivo mouse liver cytochrome P450-1A induction by propanil, diuron and linuron Chemosphere 74: 155-165, 2008

Page Top

1. 1Ohbayashi, N., Ikeda, O., Taira, N., Yamamoto, Y., Muromoto, R., Sekine, Y., Sugiyama, K., Honjoh, T., and T. Matsuda LIF- and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation Biol. Pharm. Bull. 30:1860-1864, 2007
2. 2Sekine, Y., Tsuji, S., Ikeda, O., Sugiyma, K., Oritani, K., Shimoda, K., Muromoto, R., Ohbayashi, N., Yoshimura, A., and T. Matsuda STAP-2 regulates integrin-mediated T-cell adhesion through protein degradation of FAK J. Immunol. 179：2397-2407, 2007
3. 3Sekine, Y., Ikeda, O., Hayakawa, Y., Tsuji, S. Imoto, S., Aoki, N., Sugiyama, K., and T. Matsuda DUSP22/LMW-DSP2 regulates estrogen receptor α-mediated signaling through dephosphorylation of Ser-118 Oncogene 26: 6038-6049, 2007
4. 4Ikeda, O., Sekine, Y., Kakisaka, M., Tsuji, S., Muromoto, R., Ohbayashi, N., Oritani, K., Yoshimura A., and T. Matsuda STAP-2 regulates c-Fms/M-CSF receptor signaling in murine macrophage Raw 264.7 cells Biochem. Biophys. Res. Commun. 358: 931-937, 2007
5. 5Shide, K., Shimoda, K., Kamezaki, K., Kakumitsu, H., Kumamo, T., Numata, A., Ishikawa, F., Takenaka, K., Yamamoto, K., Matsuda, T., and M. Harada Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Leuk. Res. 31: 1085-1092, 2007
6. 6Sekine, Y., Tsuji, S., Ikeda, O., Kakisaka, M., Sugiyama, K., Yoshimura A., and T. Matsuda Leukemia inhibitory factor-induced phosphorylation of STAP-2 on tyrosine-250 is involved in its STAT3-enhancing activity Biochem. Biophys. Res. Commun. 356:517-522, 2007
7. 7Shimoda, H. K., Yamamoto, M., Shide, K., Kamezaki, K., Matsuda, T., Ogawa, K., Harada, M., and K.Shimoda Chronic thrombopoietin overexpression induces mesangioproliferative glomerulopathy in mice Am. J. Hematol. 82：802-806, 2007

Page Top

1. 1Muromoto, R., K. Nakao, T. Watanabe, N. Sato, Y. Sekine, K. Sugiyama, K.Oritani, K. Shimoda and T. Matsuda Physical and functional interactions between Daxx and STAT3 Oncogene 25: 2131-2136, 2006
2. 2Sato, N., N. Kamada, R. Muromoto, T. Kawai, K. Sugiyama, T. Watanabe, S. Imoto, Y. Sekine, N. Ohbayashi, M. Ishida, S. Akira and T. Matsuda Phosphorylation of threonine-265 in Zipper-interacting protein kinase plays an important role in its activity and is induced by IL-6 family cytokines Immunol. Lett. 103: 127-134, 2006
3. 3Sekine, Y., T. Yumioka, T. Yamamoto, R. Muromoto, S. Imoto, K. Sugiyma, K. Oritani, K. Shimoda, M. Minoguchi, S. Akira, A. Yoshimura and T. Matsuda Modulation of Toll-like receptor 4 signaling by a novel adaptor protein STAP-2 in macrophages J. Immunol. 176: 380-389, 2006
4. 4Muromoto,R., K. Okabe, M. Fujimuro, K. Sugiyama, H. Yokosawa, T. Seya and T. Matsuda Physical and functional interactions between STAT3 and Kaposi's Sarcoma-associated Herpesvirus-encoded LANA FEBS Lett. 580: 93-98, 2006
5. 5Sekine, Y., S. Tsuji, O. Ikeda, N. Sato, N. Aoki, K. Aoyama, K. Sugiyama and T. Matsuda Regulation of STAT3-mediated signaling by LMW-DSP2 Oncogene 25: 5801-5806, 2006
6. 6Muromoto, R., M. Ishida, K. Sugiyama, Y. Sekine, K. Oritani, K. Shimoda and T. Matsuda Sumoylation of Daxx regulates IFN-induced growth suppression of B-lymphocytes and the hormone receptor-mediated transactivation J. Immunol. 177: 1160-1170, 2006
7. 7Takeuchi, S., Matsuda, T., Kobayashi, S., Takahashi, T., and H. Kojima In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR) alpha and PPAR gamma and quantitative analysis of in vivo induction pathway Toxicol. Appl. Pharmacol. 217:235-244, 2006
8. 8Funakoshi-Tago, M., Pelletier, S., Matsuda, T., Parganas, E., and J. N. Ihle Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2 EMBO J. 25:4763-4772, 2006

Page Top

1. 1Sekine, Y., T. Yamamoto, T. Yumioka, K. Sugiyama, S.Tsuji, K.Oritani, K. Shimoda, M. Minoguchi, A. Yoshimura and T. Matsuda Physical and functional interactions between STAP-2/BKS and STAT5 J. Biol. Chem. 280: 8188-8196, 2005
2. 2Kamezaki K, Shimoda K, Numata A, Haro T, Kakumitsu H, Yoshie M, Yamamoto M, Takeda K, Matsuda T, Akira S, Ogawa K, Harada M Roles of Stat3 and ERK in G-CSF Signaling Stem Cells 23: 252-263, 2005.
3. 3Takeuchi, S., M. Iida, S. Kobayashi, K. Jin, T. Matsuda, H. Kojima Differential Effects of Phthalate Esters on Transcriptional Activities via Human Estrogen Receptors alpha and beta, and Androgen Receptor Toxicology 210: 223-233, 2005.
4. 4Yokoyama, T., S. Okamura, Y. Asano, K. Kamezaki, A. Numata, H. Kakumitsu, K. Shide, H. Nakashima, T. Kanaji, Y. Sekine, Y. Mizuno, J. Okamura, T. Matsuda, M. Harada, Y. Niho, K. Shimoda A novel juxtamembrane intracellular G-CSF receptor gene mutation in a patient with severe congenital neutropenia augments the proliferation activity by G-CSF not through the MAP kinase cascade Int. J. Hematology 82: 28-34, 2005
5. 5Imoto, S., K. Sugiyama, Y. Sekine and T. Matsuda Roles for lysine residues of the MH2 domain of Smad3 in transforming growth factor-beta signaling FEBS Lett. 579: 2853-2862, 2005
6. 6Hosoi, T., Y. Okuma, T. Matsuda and Y. Nomura Novel pathway for LPS-induced afferent vagus nerve activation: possible role of nodose ganglion Auton. Neurosci. 120: 104-107, 2005
7. 7Sato, N., R. Tsuruma, S. Imoto, Y. Sekine, R. Muromoto, K. Sugiyama and T.Matsuda Nuclear retention of STAT3 through the coiled-coil domain regulates its activity Biochem. Biophys. Res. Commun. 336: 617-624, 2005
8. 8Sato, N., T. Kawai, K. Sugiyama, R. Muromoto, S. Imoto, Y. Sekine, M. Ishida, S. Akira and T. Matsuda Physical and functional interactions between STAT3 and ZIP kinase Int. Immunol. 17: 1543-1552, 2005
9. 9Kakumitsu, H., K. Kamezaki, K. Shimoda, K. Karube, T. Haro, A. Numata, K. Shide, T. Matsuda, K. Oshima, and M. Harada Transgenic mice overexpressing murine Thrombopoietin develop myelofibrosis and osteosclerosis. Leuk. Res. 29: 761-769, 2005
10. 10Tsuchiya, H., T. Matsuda, H. Harashima and H. Kamiya Cytokine induction by a bacterial DNA-specific modified base Biochem. Biophys. Res. Commun. 326:777-781, 2005
11. 11Nagakawa, O., Junicho, A., Akashi, T., Koizumi, K., Matsuda, T., Fuse, H., Saiki, I. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells. Oncol Rep. 13:1217-1221, 2005.

Page Top

1. 1Yamamoto, T., S. Imoto, Y. Sekine , K. Sugiyama,T. Akimoto., A. Muraguchi and T. Matsuda Involvement of NF-kappaB in TGF-beta-mediated suppression of IL-4 signaling Biochem. Biophys. Res. Commun. 313: 627-634, 2004.
2. 2Kanie, T., A. Abe, T. Matsuda, Y. Kuno, M. Towatari, T. Yamamoto, H. Saito, N. Emi, T. Naoe TEL-Syk fusion constitutively activates PI3-K/Akt-, MAPK- and JAK2-independent STAT5 signal pathways Leukemia 18: 548-555, 2004
3. 3Muromoto, R., K. Sugiyama, A. Takachi, S. Imoto, N. Sato, T. Yamamoto, K. Oritani, K. Shimoda and T. Matsuda Physical and Functional Interactions between Daxx and DNA Methyltransferase 1 Associated Protein, DMAP1 J. Immunol. 172: 2985-2993, 2004
4. 4Sekine, Y., T. Yamamoto, T. Yumioka, S. Imoto, H. Kojima, and T. Matsuda Cross-talk between endocrine-disrupting chemicals and cytokine signaling through estrogen receptors Biochem. Biophys. Res. Commun. 315: 692-698, 2004
5. 5Muromoto, R., K. Sugiyama, T. Yamamoto, K. Oritani, K. Shimoda and T. Matsuda Physical and Functional Interactions between Daxx and TSG101 Biochem. Biophys. Res. Commun. 316: 827-833, 2004
6. 6Imoto, S., K. Sugiyama, T. Yamamoto and T. Matsuda The RING domain of PIASy is involved in the suppression of bone morphogenetic protein-signaling pathway Biochem. Biophys. Res. Commun. 319: 275-282, 2004
7. 7Haro, T., K. Shimoda, H. Kakumitsu, K. Kamezaki, A. Numata, F. Ishikawa, Y. Sekine, R. Muromoto, T. Matsuda and M. Harada Tyrosine kinase 2 interacts with and phosphorylates Rack-1, a WD motif containing protein J. Immunol. 173: 1151-1157, 2004
8. 8Kamezaki, K., K. Shimoda, A. Numata, T. Matsuda, K-I. Nakayama, M. Harada The role of Tyk2, Stat1 and Stat4 in LPS-induced endotoxin signals Int. Immunol. 16: 1173-1179, 2004
9. 9Hosoi, T., T. Wada, S. Suzuki, Y. Okuma, S. Akira, T. Matsuda and Y. Nomura Bacterial endotoxin induces IL-20 expression in the primary cultured glial cells Mol. Brain Res. 130: 23-29, 2004
10. 10Hosoi, T., Y. Okuma, T. Kawagishi, Qi, X, T. Matsuda and Y. Nomura Bacterial endotoxin induces STAT3 activation in the mouse brain Brain Res. 1023: 48-53, 2004.
11. 11Hosogia, M., H. Tonogaito, A. Aioi, K. Hamada, K. Shimoda, R. Muromoto, T. Matsuda and Y. Miyachi Hapten-Induced Contact Hypersensitivity is enhanced in Tyk2-Deficient Mice J. Dermatol. Sci. 36: 51-56, 2004
12. 12Watanabe, K., K. Saito, M. Kinjo, T. Matsuda, M. Tamura, S. Kon and T. Uede Molecular dynamics of STAT3 on IL-6 signaling pathway in living cells Biochem. Biophys. Res. Commun. 324: 1264-1273, 2004
13. 13Matsuda T., J. Feng, B. A. Witthuhn, Y. Sekine and J. N. Ihle Determination of the transphosphorylation sites of Jak2 kinase Biochem. Biophys. Res. Commun. 325: 586-594, 2004
14. 14Nakagawa, O., Akashi, T., Hayakawa, Y., Junicho, A., Koizumi, K., Fujiuchi, Y., Furuya Y., Matsuda, T., Fuse, H., and Saiki, I. Differntial expression of integrin subunits in DU-145/AR prostate cancer cells Oncol. Report 12: 837-841, 2004.
15. 15Junicho, A. O. Nakagawa, H. Kishi, T. Matsuda, Y. Furuya, and H. Fuse. Vasoactive intestinal peptide inhibits MHC class I expression via inhibition of IFN-Γ induced STAT1 activation in DU-145/AR cells BJU International 94: 913-914, 2004.

Page Top

1. 1Sato, N., T. Yamamoto, Y. Sekine, T. Yumioka, A. Junicho, H. Fuse and T. Matsuda Involvement of Heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3 Biochem. Biophys. Res. Commun. 300: 847-852, 2003.
2. 2Minoguchi, M., S. Minoguchi, D. Aki, A. Joo, T.Yamamoto, T. Yumioka, T. Matsuda and A.Yoshimura STAP-2/BKS, an adaptor/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif J. Biol. Chem. 278:11182-11189, 2003.
3. 3Muromoto R, T. Yamamoto, T. Yumioka, Y. Sekine, K. Sugiyama, K. Shimoda, K. Oritani and T. Matsuda Daxx enhances Fas-mediated apoptosis in a murine pro-B cell line, BAF3 FEBS Lett. 540: 223-228, 2003.
4. 4Yamamoto, T., N., Sato, Y. Sekine, T. Yumioka, S. Imoto, A. Junicho, H. Fuse and T. Matsuda Molecular interactions between STAT3 and protein inhibitor of activated STAT3, and androgen receptor Biochem. Biophys. Res. Commun. 306: 610-615, 2003
5. 5Yamamoto, T., T. Yumioka, Y. Sekine , N. Sato, M. Minoguchi, A. Yoshimura, and T.Matsuda Regulation of FcepcilonRI-mediated signaling by an adaptor protein STAP-2/BKS in rat basophilic leukemia RBL-2H3 cells Biochem. Biophys. Res. Commun. 306: 767-773, 2003
6. 6Imoto, S., K. Sugiyama, R. Muromoto, N. Sato, T. Yamamoto, and T. Matsuda Regulation of TGF-beta Signaling by Protein Inhibitor of activated STAT, PIASy through Smad3 J. Biol. Chem. 278: 34253-34258, 2003
7. 7Kato, K., K. Kamezaki, K. Shimoda, A. Numata, T.Haro, K. Aoki, F. Ishikawa, K. Takase, H. Ariyama, T. Matsuda, T. Miyamoto, K. Nagafuji, H. Gondo, K-I.Nakayama, M. Harada Intracellular signal transduction of Interferon on the suppression of hematopoietic progenitor cell growth Br. J. Hematol. 123:528-535,2003.
8. 8Aoki, K., K. Shimoda, K. Oritani, T. Matsuda, K. Kamezaki, R. Muromoto, A. Numata, S. Tamiya, T. Haro, F. Ishikawa, K. Takase, T.Yamamoto, T. Yumioka, T. Miyamoto, K. Nagafuji, H. Gondo, S. Nagafuchi, K-I. Nakayama, M. Harada Limitin, an interferon-like cytokine, transduces inhibitory signals on B cell growth through activation of Tyk2, but not Stat1, followed by the induction and nuclear translocation of Daxx Exp. Hematol. 31: 1317-1322, 2003.

Page Top

1. 1Yamamoto, T., Y. Sekine, K. Kashima, A. Kubota, N. Sato, N. Aoki and Matsuda, T. The nuclear isoform of protein tyrosine phosphatase TC-PTP regulates Interleukin-6-mediated signaling pathway through STAT3 dephosphorylation Biochem. Biophys. Res. Commun. 297: 811-817, 2002.
2. 2Shimoda, K., K. Kamesaki, A. Numata, K. Aoki, T. Matsuda, K. Oritani, S. Tamiya, K. Kato, K. Takase, R. Imamura, T. Yamamoto, T. Miyamoto, K. Nagafuji, H. Gondo, S. Nagafuchi, K. Nakayama, and M. Harada Tyk2 is required for the induction and nuclear translocation of Daxx which regulates interferon-alpha-induced suppression of B lymphocyte formation J. Immunol. 169: 4707-4711, 2002.
3. 3Kishi, H., Z, -X. Jin., X. -C. We., T. Nagata, T. Matsuda, S. Saito and A. Muraguchi Cooperative binding of c-Myb and Pax-5 activates the RAG-2 promoter in immature B cells. Blood 99: 576-583, 2002
4. 4Nagata, T., H. Kishi., Q. -L. Leu., T. Matsuda., T. Imanaka, K. Tsukada, D. Kang and A. Muraguchi The regulation of deoxyribonuclease activities in subcellular compartments of activated thymocytes Immunology 105: 399-406, 2002
5. 5Shimoda, K.,H. Tsutui, K. Aoki, K. Kato, T. Matsuda, A. Numata, K. Takase, T. Yamamoto, H. Nukina, T. Hoshino, Y. Asano, H. Gondo, T. Okamura, S. Okamura, K. Nakayama, K. Nakanishi, Y. Niho and M. Harada Partial Impairment of IL-12 and IL-18 Signaling in Tyk2-deficient Mice Blood 99: 2094-2099, 2002.
6. 6Nakagawa, O., Murata, J., Junicho, A., Matsuda, T., Fujiuchi, Y., Fuse, H., and Saiki, I Vasoactive intestinal peptide (VIP) enhances the cell motility of androgen receptor-transfected DU-145 prostate cancer cells (DU-145/AR) Cancer Lett. 176: 93-99, 2002.
7. 7Yamamoto, T., F. Saatcioglu and T. Matsuda Cross-talk between bone morphogenic proteins and estrogen receptor signaling Endocrinology 143: 2635-2642, 2002.
8. 8Wei, X. -C., H. Kishi, Z. -X. Jin, W. -P. Zhao, S. Kondo, T. Matsuda, S. Saito and A. Muraguchi Characterization of chromatin structure and enhancer elements for murine recombination activating gene-2 J. Immunol. 169: 873-881, 2002
9. 9Jin, Z. -X., H. Kishi, X. -C., Wei, T. Matsuda, S. Saito and A. Muraguchi LEF-1 binds and activates the recombination-activating gene-2 promoter together with c-Myb and Pax-5 in immature B cells J. Immunol. 169: 3783-3792, 2002
10. 10Fukui, A., T. Yuasa-Nakagawa, Y. Murakami, K. Funami., N. Kishi., Matsuda, T., T. Fujita., T. Seya., and S. Nagasawa Mapping of the sites responsible for factor I-cofactor activity for cleavage of C3b and C4b on human C4b-binding protein (C4bp) by deletion mutagenesis J. Biochem. 132: 719-728, 2002.

Page Top

1. 1Yamamoto, T, T. Matsuda, A. Junicho, H. Kishi , A.Yoshimura and A. Muraguchi Hematopoietic cell-specific adapter proteins, SLP-76 and BLNK, effectively activate NF-AT as well as NF-κB by Syk and Tec PTKs in non-lymphoid cell lines FEBS Lett. 491: 272-278, 2001
2. 2Yamamoto, T., T. Matsuda, A. Muraguchi, K. Miyazono and M. Kawabata Cross-talk between IL-6 and TGF-beta signaling in hepatoma cells FEBS Lett. 492: 247-253, 2001
3. 3Matsuda, T., A. Junicho, T. Yamamoto, H. Kishi, K. Korkmaz, F. Saatcioglu, H. Fuse and A. Muraguchi Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells Biochem. Biophys. Res. Commun. 283: 179-187, 2001
4. 4Matsuda, T.,T. Yamamoto, A. Muraguchi and F. Saatcioglu Cross-talk between TGF-beta and estrogen receptor signaling through Smad3 J. Biol. Chem. 276: 42907-42914, 2001

Page Top

1. 1Matsuda,T., T. Yamamoto, H. Kishi, A. Yoshimura and A. Muraguchi SOCS-1 can suppress CD3zeta-and Syk-mediated NF-AT activation in a non-lymphoid cell line FEBS Lett. 472: 235-240, 2000
2. 2Fujishiro,Y., H. Kishi, T. Matsuda, H. Fuse and A. Muraguchi Lactatedehydrogenase-A-dependent surface expression of immature thymocyte antigen-1; an implication for a novel trafficking function of lactate-dehydrogenase-A during T cell development Eur. J. Immunol. 30: 516-524, 2000
3. 3Kishi, H., X. -C. Wei., Z, -X. Jin., Y. Fujishiro., T. Nagata., T. Matsuda and A. Muraguchi Distinct factors, GATA-3 and Pax-5, may reciprocally regulate the murine RAG2 promoter in T- and B-lineage cells Blood 95: 3845-3852, 2000
4. 4Nagata, T., H. Kishi., Q. -L. Leu., T. Yoshino., T. Matsuda., Z, -X. Jin., K. Maruyama, K. Tsukada and A. Muraguchi Possible involvement of cyclophilin B and caspase-activated Dnase (CAD) in the induction of chromosomal DNA-degradation in TCR-stimulated thymocytes. J. Immunol. 165: 4281-4289, 2000
5. 5Shimoda, K., K. Kato., K. Aoki., T. Matsuda., A. Miyamoto., M. Shibamori., M. Yamashita., A. Numata., K. Takase, S. Kobayashi, S. Shibata, Y. Asano, H. Gondo., K. Sekiguchi., K. Nakayama., T. Nakayama., T. Okamura., S. Okamura., Y. Niho, K. Nakayama Tyk2 plays a restricted role in IFNgamma signaling, although it is required for IL-12-mediated T cell function Immunity 13: 561-571, 2000
6. 6Junicho, A, T. Matsuda, T. Yamamoto, H. Kishi , K. Korkmaz, F. Saatcioglu, H. Fuse and A. Muraguchi Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells Biochem. Biophys. Res. Commun. 278: 9-13, 2000
7. 7Matsuda T., and T. Hirano　 Interleukin-6 (IL-6) 　Cytokine Reference Academic Press, pp537-563, 2000.
8. 8Yamamoto, T., T. Matsuda, A. Junicho, H. Kishi , F. Saatcioglu, and A. Muraguchi　Cross-talk between signal transducer and activator of transcription 3 and estrogen receptor signaling　FEBS Lett. 486：143-148, 2000
9. 9Yasukawa, H.,H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, T. Imaizumi, T. Matsuda, J.N. Ihle and A. Yoshimura The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop　EMBO J. 18: 1309-1320, 1999
10. 10Tong, J. J., H. Kishi, T. Matsuda and A. Muraguchi A bone marrow-derived stromal cell line, ST-2, can support the differentiation of fetal thymocytes from the CD4-CD8- double negative to the CD4+CD8+ double positive differentiation stage in vitro 　Immunology 97: 672-678,1999
11. 11Feng, J., B. A. Witthuhn, T. Matsuda, F. Kohlhuber, I. M. Kerr and J. N. Ihle Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop 　Mol. Cell. Biol. 17: 2497-2501, 1997
12. 12Matsuda, T., M. Takahashi-Tezuka, T. Fukada, Y. Okuyama, Y. Fujitani, S. Tsukada, H. Mano, H. Hirai, O.N. Witte, and T. Hirano 　Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the IL-6 family of cytokines　　Blood, 85: 627-633,1995
13. 13Matsuda, T., T. Fukada, M. Takahashi-Tezuka, Y. Okuyama, Y. Fujitani, Y. Hanazono, H. Hirai, and T. Hirano 　Activation of Fes tyrosine kinase by gp130, an Interleukin-6 family cytokine signal transducer, and their association 　J. Biol. Chem. 270:11037-11039, 1995
14. 14Nakajima, K., T. Matsuda, Y. Fujitani, H. Kojima, Y. Yamanaka, K. Nakae, T. Takeda and T. Hirano Signal transduction through IL-6 receptor: involvement of multiple protein kinases, Stat factors and a novel H-7-sensitive pathway 　Ann. New York Acad. Sci. 762: 55-70, 1995
15. 15Matsuda, T., Y. Yamanaka and T. Hirano Interleukin-6-induced tyrosine phosphorylation of multiple proteins in murine hematopoietic lineage cells 　Biochem. Biophys. Res. Commun. 200: 821-828, 1994
16. 16Matsuda, T. and T. Hirano Association of p72 tyrosine kinase with Stat factors and its activation by IL-3, IL-6 and G-CSF 　Blood 83: 3457-3461, 1994
17. 17Matsuda, T., and T. Hirano　Establishment of the ELISA for murine soluble gp130, a signal transducer for the IL-6 family cytokine and its detection in the ascitic fluids of tumor-bearing mice. Biochem. Biophys. Res. Comm. 202: 637-642, 1994
18. 18Matsuda, T., T. Nakajima, T. Kaisho, K. Nakajima and T. Hirano Interleukin 6 receptor and signal transduction　Advances in Cell and Molecular Biology of Membranes and Organelles 3: 65-92, 1994.
19. 19Hirano, T., T. Matsuda, and K. Nakajima 　Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily Stem Cells 12: 262-277, 1994
20. 20Iwano, M., K. Dohi, E. Hirata, N. Kurumatani, Y. Horii, H. Shiiki, A. Fukatsu, T. Matsuda, T. Hirano, T. Kishimoto and H. Ishikawa 　Urinary levels of IL-6 in patients with active lupus nephritis　　Clinical Nephrology 40: 16-21, 1993
21. 21Suematsu, S., T. Matsusaka, T. Matsuda, T. Hirano and T. Kishimoto Interleukin-6 in Myeloma/Plasmacytoma Int. Rev. Exp. Pathol. 34: 91-98, 1993
22. 22Suematsu, S., T. Matsusaka, T. Matsuda, S. Ohno, J. Miyazaki, K. Yamamura, T. Hirano, and T. Kishimoto　　Generation of transplantable plasmacytomas with t(12;15) in IL-6 transgenic mice　Proc. Natl. Acad. Sci. USA. 89:232-235, 1992
23. 23Kasukabe, T., J. Okabe-Kado, Y. Honma, N. Hozumi, T. Matsuda and T. Hirano Characterization of growth inhibitory factors for mouse monocytic leukemia cells Leuk. Res. 16: 139-144, 1992
24. 24Kobayashi, I., T. Matsuda, T. Saito, K. Yasukawa, H. Kikutani, T. Hirano, T. Taga and T. Kishimoto Abnormal distrubution of IL-6 receptor in aged MRL/Ipr mice: elevanted expression on B cells and absence on CD4+ cells 　Int. Immunol. 4:1407-1412, 1992
25. 25Matsuda, T., T. Kishimoto Interleukin 6 Encyclopedia of Immunology 2: 917-919, 1992
26. 26Tang, B., T. Matsuda, S. Akira, N. Nagata, S. Ikehara, T. Hirano, and T. Kishimoto 　Age-associated increase in interleukin-6 in MRL/lpr mice 　Int. Immunol. 3: 273-278, 1991
27. 27Fukatsu, A., S. Matsuo, H. Tamai, N. Sakamoto. T. Matsuda and T. Hirano Distribution of interleukin 6 in normal and diseased human kidney　Lab. Invest. 65: 61-66, 1991
28. 28Yasukawa, K., T. Saito, T. Fukunaga, Y. Sakimori, Y. Koishihara, H. Fukui, Y. Ohsugi, T. Matsuda, H. Yawata, T. Hirano, T. Taga and T. Kishimoto 　Purification and Characterization of Soluble Human IL-6 Receptor Expressed in CHO Cells J. Biochem. 108: 673-676, 1990
29. 29Kameda, T., N. Matsuzaki, K. Sawai, T. Oakda, F. Saji, T. Matsuda, T. Hirano, T. Kishimoto, and O. Tanizawa Production of interleukin-6 by normal human trophoblast　Placenta 11: 205-213, 1990
30. 30Ishimi, Y., C. Miyaura, C. He Jin, T. Akatsu, Y. Nakamura, A. Yamaguchi, S. Yoshiki, T. Matsuda, T. Hirano, T. Kishimoto, and T. Suda IL-6 is produced by osteoblasts and induces bone resorption J. Immunol. 145: 3297-3303, 1990
31. 31Adelman D. C., Matsuda T, Hirano T, Kishimoto T, Saxon A　Elevated serum interleukin-6 associated with a failure in B cell differentiation in common variable immunodeficiency J. Allergy Clin. Immunol. 86:512-521, 1990
32. 32Hirano, T., T. Taga, T. Matsuda, M. Hibi, S. Suematsu, B. Tang, M. Murakami, and T. Kishimoto Interleukin 6 and its receptor in the immune response and hematopoiesis　Int. J. Cell Cloning 8:155-167, 1990
33. 33Matsuda, T., and T. Hirano Interleukin 6 (IL-6) Biotherapy 2: 363-373, 1990
34. 34Matsuda, T., T. Hirano, S. Nagasawa, and T. Kishimoto Identificatioin of alpha2-macroglobulin as a carrier protein for interleukin 6　J. Immunol. 142: 148-152, 1989
35. 35Miyaura, C., C. H. Jin, Y. Yamaguchi, M. Tomida, M. Hozumi, T. Matsuda, T. Hirano, T. Kishimoto, and T. Suda Production of interleukin 6 and its relation to macrophage differentiation of mouse myeloid leukemia cells (M1) treated with differentiation-inducing factor and 1alpha,25-dihydroxyvitamin D 　Biochem. Biophys. Res. Comm. 158: 660-666, 1989
36. 36Miyasaka, N., K. Sato, J. Hashimoto, H. Kohsaka, K. Yamamoto, M. Goto, K. Inoue, Y. Matsuda, T. Hirano, T. Kishimoto, and K. Nishioka　　Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium　　Clin. Immunol. Immunopathol. 52: 238-247, 1989
37. 37Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, and T. Kishimoto Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130　Cell 58: 573-581, 1989
38. 38Yoshizaki, K., T. Matsuda, N. Nishimoto, T. Kuritani, L. Taeho, K. Aozasa, T. Nakahata, H. Kawai, H. Tagoh, T. Komori, S. Kishimoto, T. Hirano, and T. Kishimoto Pathological significance of interleukin 6 (IL-6/BSF-2) in Castleman's disease Blood 74:1360-1367, 1989
39. 39Suematsu, S., T. Matsuda, K. Aozasa, S. Akira, N. Nakano, S. Ohno, J. Miyazaki, K. Yamamura, T. Hirano, T. Kishimoto IgG1 plasmacytosis in interleukin 6 transgenic mice 　Proc. Natl. Acad. Sci. USA. 86:7547-7551, 1989
40. 40Horii, Y., A. Muraguchi, M. Iwano, T. Matsuda, T. Hirayama, H. Yamada, Y. Fujii, K. Dohi, H. Ishikawa, Y. Ohmoto, K. Yoshizaki, T. Hirano, and T. Kishimoto Involvement of interleukin-6 in mesangial proliferative glomerulonephritis J. Immunol. 143: 3949-3955, 1989
41. 41Hirano, T., T. Taga, K. Yamasaki, T. Matsuda, B. Tang, A. Muraguchi, Y. Horii, S. Suematsu, Y. Hirata, H. Yawata, M. Shimizu, M. Kawano, and T. Kishimoto　　A multifunctional cytokine, IL-6/BSF-2 and its receptor Int. Arch. Allergy Appl. Immunol. 88:29-33, 1989
42. 42Hirano, T., T. Taga, K. Yamasaki, T. Matsuda, B. Tang, S. Suematsu, Y. Horii, Y. Hirata, H. Yawata, A. Muraguchi, M. Kawano, M. Shimizu, and T. Kishimoto Interleukin 6 and its receptor: Pathological role in autoimmunity and lymphoid malignancy Adv. Immunopharmacol. 4:161-168, 1989
43. 43Hirano, T., T. Taga, K. Yamasaki, T. Matsuda, S. Suematsu, B. Tang, Y. Hirata, H. Yawata, M. Hibi, S. Natsuka, S. Akira, K. Yoshizaki, M. Kawano, K. Yamamura, and T. Kishimoto Interleukin 6 and its receptor 　Proceedings of the Mochida Memorial Symposium on Recent Progress in Cytokine Research Medical View Co. Ltd, Tokyo, pp265-285,1989
44. 44Hirano, T., T. Taga, K. Yamasaki, T. Matsuda, Y. Hirata, H. Yawata, O. Tanabe, S. Akira, and T. Kishimoto　Molecular cloning of the cDNAs for interleukin-6/B cell stimulatory factor-2 and its receptor Ann. New York Acad. Sci. 557: 167-180, 1989
45. 45Matsuda, T., S. Suematsu, M. Kawano, K. Yoshizaki, B. Tang, O. Tanabe, T. Hirano, and T. Kishimoto IL-6/BSF2 in nomal and abnormal regulation of immune responses　Ann. New York Acad. Sci. 557: 466-477, 1989
46. 46Anderson, U., and T. Matsuda Human interleukin 6 and tumor necrosis factor alpha production studied at a single-cell level Eur. J. Immunol. 19:1157-1160, 1989
47. 47Kishimoto, T., T. Taga, K. Yamasaki, T. Matsuda, B. Tang, A. Muraguchi, Y. Horii, S. Suematsu, Y. Hirata, H. Yawata, M. Shimizu, M. Kawano, and T. Hirano Normal and abnormal regulation of human B cell differentiation by a new cytokine, BSF-2/IL-6 Mechanisms of Lymphocyte Activation and Immune Regulation, vol 2 edited by S. Gupta, and W. E. Paul., Plenum Publishing Corporation, pp135-143, 1989
48. 48Taga, T., K. Yamasaki, T. Matsuda, S. Suematsu, B. Tang, T. Hirano, and T. Kishimoto Differentiation and regulation of immunocompetent cells:interleukin 6 in immune regulation 　Progress in Allergy and Clinical Immunology. Editors W. J. Pichler, B. M. Stadler, C. A. Dahinden, A. T. P'ecoud, P. Frei, C. H. Schneider, A. L. de Weck. Hogref e and Huber Publeshers, Toronto. 101:490-495, 1989
49. 49Yamasaki, K., T. Taga, T. Matsuda, S. Suematsu, T. Hirano, and T. Kishimoto Interleukin-6 and its receptor Lymphokine Receptor Interactions. Eds D. Fradelizi, J. Bertoglio. Colloque INSERM/John Libbey Eurotext Ltd. 179, pp. 143-150, 1989
50. 50Matsuda, T., K. Yamasaki, T. Taga, T. Hirano, and T. Kishimoto Current concepts of B cell modulation Int. Rev. Immunol. 5:97-109, 1989
51. 51Kishimoto, T., T. Taga, T. Matsuda, M. Hibi, S. Suematsu, B. Tang, H. Yawata, Y. Hirata, K. Yamasaki, and T. Hirano Interleukin 6 and its receptor in immune regulation Prog. Immunol. 7: 633-640, 1989
52. 52Kawano, M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. Iwato, H. Asaoku, B. Tang, O. Tanabe, H. Tanaka, A. Kuramoto, and T. Kishimoto Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas 　Nature 332: 83-85, 1988
53. 53Hirano, T., T. Matsuda, K. Hosoi, A. Okano, H. Matsui, T. Kishimoto Absence of antiviral activity in recombinant B cell stimulatory factor 2 (BSF-2) 　Immunol. Lett. 17:41-45,1988
54. 54Muraguchi, A., T. Hirano, B. Tang, T. Matsuda, Y. Horii, K. Nakajima, and T. Kishimoto The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells 　J. Exp. Med. 167: 332-344,1988
55. 55Matsuda, T., T. Hirano, and T. Kishimoto　Establishment of interleukin 6 (IL-6)/B cell stimulatory factor 2 (BSF-2)-dependent cell line and preparation of anti-IL-6/BSF-2 monoclonal antibodies　Eur. J. Immunol. 18: 951-956, 1988
56. 56Hirano, T., T. Matsuda, M. Turner, K. Sato, G. Buchan, B. Tang, N. Miyasaka, M. Shimizu, R. Maini, M. Feldmann, and T. Kishimoto　Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis Eur. J. Immunol. 18:1797-1801, 1988
57. 57Sato, T., S. Nakamura, T. Taga, T. Matsuda, T. Hirano, T. Kishimoto, and Y. Kaziro. Induction of neural differentiation in PC12 cells by B cell stimulatory factor 2/interleukin 6 　Mol. Cell. Biol. 8:3546-3549, 1988.
58. 58Bauer, J., U. Ganter, T. Geiger, U. Jacobshagen, T. Hirano, T. Matsuda, T. Kishimoto, T. Andus, G. Acs, and W. Gerok 　Regulation of interleukin-6 expression in cultured human blood monocytes and monocyte-derived macrophages　Blood 72:1134-1140, 1988
59. 59Horii, Y., A. Muraguchi, S. Suematsu, T. Matsuda, K. Yoshizaki, T. Hirano, and T. Kishimoto　Regulation of BSF-2/IL-6 production by human mononuclear cells: Macrophage-dependent synthesis of BSF-2/IL-6 by T cells　J. Immunol. 141: 1529-1535,1988
60. 60Okada, M., M. Kitahara, S. Kishimoto, T. Matsuda, T. Hirano, and T. Kishimoto　BSF-2/IL-6 functions as killer helper factor in the in vitro inducton of cytotoxic T cells　J. Immunol. 141: 1543-1549, 1988
61. 61Shimizu, S., T. Hirano, R. Yoshika, S. Sugai, T. Matsuda, T. Taga, T. Kishimoto, and S. Konda Interleukin 6(B cell stimulatory factor 2)-dependent growth of a Lennert's lymphoma-derived T. cell line(KT-3)　Blood 72: 1826-1828, 1988
62. 62Kawano, M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. Iwato, H. Asaoku, B. Tang, O. Tanabe, H. Tanaka, A. Kuramoto, and T. Kishimoto Interleukin 6 (BSF2/IL-6) is an autocrine growth factor for human multiple meylomas Proc. Japan Acad. Sci. 64: 68-71, 1988
63. 63Kishimoto, T., T. Hirano, T. Taga, K. Yamasaki, T. Matsuda, B. Tang, A. Muraguchi, Y. Horii, Y. Kawanishi, Y. Hirata, H. Yawata, K. Yasukawa, Y. Watanabe, M. Shimizu, P. Heinrich, and M. Kawano A new cytokine, BSF-2/IL-6 and its receptor B cell development, edited by O. N. Witte, N. Klinman and M C. Howard. Alan R. Liss Inc., New York. pp.157-171, 1988
64. 64Yamada, H., T. Matsuda, M. Harada, T. Hirano, T. Kishimoto, and T. Tezuka. Keratinocyte produce BSF-2 (Interleukin-6)　Clin. Res. 36: 706, 1988
65. 65Yasukawa, K., T. Hirano, Y. Watanabe, K. Muratani, T. Matsuda, and T. Kishimoto Structure and expression of human B cell stimulatory factor 2 (BSF-2/IL-6) gene EMBO J. 6: 2939-2945, 1987
66. 66Kishimoto, T., T. Taga, K. Yasukawa, Y. Watanabe, T. Matsuda, K. Nakajima, and T. Hirano Molecular structure and immunological function of human B cell differentiation factor (BSF2) Molecular basis of lymphokine action, edited by D.R.Webb, C. W. Pierce, and S. Cohen, The Human Press Inc. pp123-136, 1987
67. 67Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, S. Tsunasawa, F. Sakiyama, H. Matsui, Y. Takahara, T. Taniguchi, and T. Kishimoto　　Complementary DNA for a novel human inteleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin　Nature 324: 73-76, 1986
68. 68Matsuda, T., S. Nagasawa, T. Koide, and J. Koyama　Limited proteslysis of a chemically modified third component of human complement, C3, by cathepsin G of human leukocytes　J. Biochem. 98: 229-236, 1985
69. 69Matsuda, T., T. Seya, and S. Nagasawa　Location of the inter-chain disulfide bonds of the third component of human complement. Biochem. Biophys. Res. Commun. 127: 264-269, 1985

Page Top